Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for respiratory viral diseases. The company is advancing investigational antiviral agents designed to be potent against difficult-to-treat or resistant virus strains, with an emphasis on safety and simple dosing. On April 1, 2024, Traws Pharma, then known as Onconova Therapeutics, Inc., merged with Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company. Before the merger, the company's business focused on discovering and developing cancer treatments. After the merger, the business expanded to include developing therapies for respiratory viral diseases. Following the merger, Traws Pharma has four clinical programs. These include tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor intended as a single-dose treatment for bird flu and seasonal influenza. Tivoxavir marboxil works by inhibiting the cap-dependent endonuclease (CEN) enzyme, which is crucial for influenza virus replication, thereby impeding replication of influenza A or B and bird flu viral strains. Another program is ratutrelvir, an inhibitor of the main protease (3CL protease) of the SAR-CoV-2 virus, which causes COVID-19. The company also continues to develop narazaciclib (ON 123300), a multi-targeted kinase inhibitor for solid tumors and hematological malignancies, used alone or with other anti-cancer therapies, and rigosertib, investigated alone or in combination for various cancers.